Japanese single and multiple ascending dose (JSMAD), safety, tolerability, pharmacokinetics (PK) and Pharmacodynamics (PD) study of AZD5069 - JSMAD

Exclusion Criteria

• - History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject’s ability to participate in the study.
• - History or presence of gastrointestinal, hepatic or renal disease or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs
• - Any clinically significant illness/infection or medical/surgical procedure or trauma, as judged by the Principal Investigator, within 4 weeks of the first administration of investigational product.
• - Any clinically significant abnormalities in clinical chemistry, haematology or urinalysis as judged by the Investigator